Panbela Therapeutics’ (PBLA) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Panbela Therapeutics (NASDAQ:PBLA – Free Report) in a research report sent to investors on Thursday, Benzinga reports. HC Wainwright also issued estimates for Panbela Therapeutics’ Q3 2024 earnings at ($1.63) EPS, Q4 2024 earnings at ($1.61) EPS, FY2024 earnings at ($6.76) EPS, FY2025 earnings at ($4.44) […]

Leave a Reply

Your email address will not be published.

Previous post Piper Sandler Trims Diamondback Energy (NASDAQ:FANG) Target Price to $240.00
Next post Literary pick for Aug. 18